Immutep Limited's ESMO Congress 2025 Poster Presentations

Immutep Limited announced two poster presentations at the European Society for Medical Oncology (ESMO) Congress 2025, focusing on changing the treatment landscape in first-line non-small cell lung cancer (1L NSCLC). The presentations highlighted the novel combination of eftilagimod alfa (efti) with KEYTRUDA® (pembrolizumab) and chemotherapy, which generated strong objective response rates (ORR) and disease control rates (DCR) across all PD-L1 expression levels. Notably, the combination achieved a 61.7% ORR in patients with low and no PD-L1 expression (TPS <50%), outperforming historical controls. The data suggests that efti could set a new standard of care for 1L NSCLC patients, particularly those with low PD-L1 expression, who represent over two-thirds of the patient population. The combination also demonstrated a favorable safety profile. Immutep is conducting a pivotal Phase III trial, TACTI-004, to further evaluate this combination in a global study enrolling approximately 756 patients.